-
公开(公告)号：US20050281811A1
公开(公告)日：2005-12-22
申请号：US11185373
申请日：2005-07-19
IPC分类号： A61K38/00 , A61K38/19 , A61K39/395 , C07K14/525 , C07K14/715 , C07K16/24 , C07K16/28
CPC分类号： A61K38/191 , A61K39/395 , A61K2039/505 , C07K14/525 , C07K14/715 , C07K16/2866 , C07K2317/24 , C07K2317/52 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/30 , Y10S424/809 , A61K2300/00
摘要： This invention relates to compositions and methods useful for activating LT-β receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-α and multiple subunits of lymphotoxin-β, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-β receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-β receptor which act as lymphotoxin-β receptor activating agents alone or in combination with other lymphotoxin-β receptor activating agents either in the presence or absence of lymphotoxin-α/β complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-β receptor antibodies either alone or in the presence of other lymphotoxin-β receptor activating agents to potentiate tumor cell cytotoxicity.
摘要翻译： 本发明涉及用于激活LT-β受体信号传导的组合物和方法，其又引起对肿瘤细胞的有效的抗增殖作用。 更具体地，本发明涉及在淋巴毒素-α与淋巴毒素-β的多个亚基之间形成的淋巴毒素异聚体复合物，其在淋巴毒素-β受体活化剂存在下诱导对肿瘤细胞的细胞毒性作用。 也在本发明范围内的是针对淋巴毒素-β受体的抗体，其单独或与其它淋巴毒素-β受体活化剂组合起作用，即在存在或不存在淋巴毒素-α/β复合物的情况下作为淋巴毒素-β受体活化剂 。 提供了选择这种抗体的筛选方法。 本发明还涉及使用交联的抗淋巴毒素-β受体抗体单独或在其它淋巴毒素-β受体活化剂存在下增强肿瘤细胞毒性的组合物和方法。
-
2.发明授权Active lymphotoxin-β receptor immunoglobulin chimeric protein compositions 有权活性淋巴毒素-β受体免疫球蛋白嵌合蛋白组合物公开(公告)号：US07585946B2
公开(公告)日：2009-09-08
申请号：US09767370
申请日：2001-01-23
IPC分类号： C07K14/52
CPC分类号： C12P21/00 , A61K38/00 , C07K14/70578 , C07K14/7151 , C07K2319/00 , C12P21/02
摘要： Methods for high level expression of active lymphotoxin-β receptor immunoglobulin chimeric proteins and their purification.
摘要翻译： 高水平表达活性淋巴毒素-β受体免疫球蛋白嵌合蛋白的方法及其纯化。
-
3.发明授权Method for increasing expression of active tumor necrosis factor receptor family member-Ig fusion proteins 有权增加活性肿瘤坏死因子受体家族成员-Ig融合蛋白表达的方法公开(公告)号：US08709759B2
公开(公告)日：2014-04-29
申请号：US13553604
申请日：2012-07-19
CPC分类号： C12P21/00 , A61K38/00 , C07K14/70578 , C07K14/7151 , C07K2319/00 , C12P21/02
摘要： Methods for high level expression of active lymphotoxin-β receptor immunoglobulin chimeric proteins and their purification.
摘要翻译： 高水平表达活性淋巴毒素的方法 受体免疫球蛋白嵌合蛋白及其纯化。
-
公开(公告)号：US20050037003A1
公开(公告)日：2005-02-17
申请号：US10077406
申请日：2002-02-15
IPC分类号： A61K38/00 , G01N33/566 , A61K31/00 , A61K38/17 , A61K38/19 , A61K39/00 , A61K39/395 , A61P1/00 , A61P1/04 , A61P3/00 , A61P3/10 , A61P15/00 , A61P17/00 , A61P17/06 , A61P21/00 , A61P25/00 , A61P27/00 , A61P27/02 , A61P29/00 , A61P37/00 , A61P37/02 , A61P37/06 , C07K14/715 , C07K16/24 , C07K16/28 , C12N15/02 , C12P21/08 , G01N33/00 , G01N33/577 , G01N33/68
CPC分类号： C07K14/7151 , A61K38/00 , A61K2039/505 , C07K14/715 , C07K16/241 , C07K16/2866 , C07K16/2878 , C07K2317/74 , C07K2319/00 , C07K2319/30 , Y10S514/825 , Y10S514/866 , Y10S514/885 , Y10S514/903 , Y10S930/143
摘要： This invention relates to compositions and methods comprising “lymphotoxin-β receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided.
摘要翻译： 本发明涉及包含“淋巴毒素-β受体阻断剂”的组合物和方法，其阻断淋巴毒素-β受体信号传导。 淋巴毒素-β受体阻断剂可用于治疗淋巴细胞介导的免疫疾病，更具体地，用于抑制Th1细胞介导的免疫应答。 本发明涉及作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体细胞外结构域的可溶性形式。 本发明还涉及针对作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体或其配体表面淋巴毒素的抗体的用途。 提供了一种选择可溶性受体，抗体和阻断LT-β受体信号传导的其他试剂的筛选方法。
-
5.发明申请BAFF, inhibitors thereof and their use in the modulation of B-cell response 审中-公开BAFF，其抑制剂及其在B细胞应答调节中的应用公开(公告)号：US20100233179A1
公开(公告)日：2010-09-16
申请号：US12570518
申请日：2009-09-30
IPC分类号： A61K39/395 , A61P13/12 , A61P9/00 , A61P9/12
CPC分类号： C07K16/2875
摘要： The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.
摘要翻译： 本发明提供了治疗或预防与包含BAFF及其片段，抗体，激动剂和拮抗剂的BAFF的表达相关的病症的方法。
-
公开(公告)号：US20060286111A1
公开(公告)日：2006-12-21
申请号：US11425249
申请日：2006-06-20
IPC分类号： A61K39/395 , C07K16/30
CPC分类号： A61K39/395 , A61K38/00 , A61K48/00 , C07K14/705 , C07K2319/00 , C12N2799/026
摘要： Tumor Necrosis Factor Related Ligand (TRELL) polypeptides, a novel member of the tumor necrosis factor family (TNF) and compositions comprising them are disclosed.
摘要翻译： 公开了肿瘤坏死因子相关配体（TRELL）多肽，肿瘤坏死因子家族（TNF）的新成员和包含它们的组合物。
-
公开(公告)号：US20060280722A1
公开(公告)日：2006-12-14
申请号：US11411049
申请日：2006-04-25
IPC分类号： A61K39/395 , A61K38/40 , A61K38/19 , A61K38/17
CPC分类号： A61K38/1793
摘要： Therapeutic uses of inhibitors of the Lymphotoxin Pathway to treat tumors, specifically to treat follicular lymphomas.
-
公开(公告)号：US20060252122A1
公开(公告)日：2006-11-09
申请号：US11425226
申请日：2006-06-20
IPC分类号： C12P21/06 , C07K14/525 , C07H21/04
CPC分类号： A61K39/395 , A61K38/00 , A61K48/00 , C07K14/705 , C07K2319/00 , C12N2799/026
摘要： Nucleic acids that encode Tumor Necrosis Factor Related Ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, are described.
摘要翻译： 描述了编码肿瘤坏死因子相关配体（TRELL）（肿瘤坏死因子家族（TNF））修饰TRELL的新成员的核酸。
-
公开(公告)号：US20150139992A1
公开(公告)日：2015-05-21
申请号：US14452870
申请日：2014-08-06
申请人： Jeffrey Browning , Christine Ambrose , Fabienne MacKay , Jurg Tschopp , Pascal Schneider , Jeffrey Thompson
发明人： Jeffrey Browning , Christine Ambrose , Fabienne MacKay , Jurg Tschopp , Pascal Schneider , Jeffrey Thompson
IPC分类号： C07K14/715 , C07K16/24
CPC分类号： C07K14/7151 , A61K38/17 , A61K39/00 , A61K39/395 , A61K2039/505 , C07K14/70575 , C07K16/241 , C07K2319/00
摘要： A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
摘要翻译： 提供TNF家族中的新型受体：BAFF-R。 还提供了嵌合分子和对BAFF-R的抗体及其使用方法。
-
10.发明授权Methods of screening for a compound that inhibits the interaction between BAFF and BCMA 有权筛选抑制BAFF和BCMA之间相互作用的化合物的方法公开(公告)号：US08828669B2
公开(公告)日：2014-09-09
申请号：US13401610
申请日：2012-02-21
申请人： Jeffrey Browning , Christine Ambrose , Fabienne MacKay , Jurg Tschopp , Pascal Schneider , Jeffrey Thompson
发明人： Jeffrey Browning , Christine Ambrose , Fabienne MacKay , Jurg Tschopp , Pascal Schneider , Jeffrey Thompson
IPC分类号： G01N33/53 , A61K39/395 , A61K38/17 , C07K14/705 , A61K39/00
CPC分类号： C07K14/7151 , A61K38/17 , A61K39/00 , A61K39/395 , A61K2039/505 , C07K14/70575 , C07K16/241 , C07K2319/00
摘要： A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
摘要翻译： 提供TNF家族中的新型受体：BAFF-R。 还提供了嵌合分子和对BAFF-R的抗体及其使用方法。
-
-
-
-
-
-
-
-
-
搜索结果
40 条记录 (耗时 0.024 秒)
